NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL
CURE Educated Patient CLL Webinar
Thursday, August 27, 2020
CURE® is proud to bring additional expert insight to Chronic Lymphocytic Leukemia patients and caregivers on our next Educated Patient® CLL Webinar on Thursday August 27 at 6 p.m ET. On this webinar participants will hear from the experts on topics such as BTK inhibitors, oral vs. infusion treatment options, living with CLL long-term, and shared decision-making. Participants will also have the opportunity to submit questions to be answered live by our expert panel.
Related posts